Stem Cell Therapeutics Announces Issuance of Australian Patent
October 01 2008 - 10:31AM
Marketwired
Stem Cell Therapeutics Corp. ("SCT") (TSX VENTURE: SSS) has been
issued Australian Patent No. 2003250697, entitled "Oligodendrocyte
Production from Multipotent Neural Stem Cells". This patent, issued
on August 14, 2008, covers methods of producing oligodendrocytes
from neural stem cells using granulocyte-macrophage colony
stimulating factor (GM-CSF), interleukin 3 (IL-3), or interleukin 5
(IL-5), either in vivo or in cell culture, as well as
oligodendrocyte compositions produced by such methods. This is the
first patent to issue in this patent family.
Dr. Alan Moore, President and CEO, commented as follows:
"This technology adds to the depth of our patent portfolio by
expanding the repertoire of pharmaceutical agents we can use to
activate neural stem cells, in this case to produce
oligodendrocytes. Neurodegenerative demyelinating diseases such as
multiple sclerosis are associated with loss of myelin-producing
oligodendrocytes. Further, GM-CSF fits into our "repurposing"
approach of using old drugs in new indications for expediting entry
into the marketplace. Whether we develop this technology in-house
or utilize it as an out-licensing opportunity, this patent adds to
our arsenal of commercialization opportunities."
About Stem Cell Therapeutics Corp.: Stem Cell Therapeutics Corp.
is a Canadian public biotechnology company (TSX VENTURE: SSS)
focused on the development and commercialization of drug-based
therapies to treat central nervous system diseases. SCT is a leader
in the development of therapies that utilize drugs to stimulate a
patient's own resident stem cells. The Company's programs aim to
repair neurological function lost due to disease or injury. The
Company's extensive patent portfolio of owned and licensed
intellectual property supports the potential expansion into future
clinical programs in numerous neurological diseases such as
traumatic brain injury and multiple sclerosis.
For further information on Stem Cell Therapeutics Corp., visit
www.stemcellthera.com.
These securities have not been registered under the United
States Securities Act of 1933, as amended, or the securities laws
of any state, and may not be offered or sold within the United
States or to, or for the account or benefit of U.S. persons unless
an applicable exemption from U.S. registration requirements is
available.
Except for historical information, this press release may
contain forward-looking statements, which reflect the Company's
current expectation regarding future events. These forward-looking
statements involve risk and uncertainties, which may cause but are
not limited to, changing market conditions, the successful and
timely completion of clinical studies, the establishment of
corporate alliances, the impact of competitive products and
pricing, new product development, uncertainties related to the
regulatory approval process and other risks detailed from time to
time in the Company's ongoing quarterly and annual reporting.
The TSX Venture Exchange does not accept responsibility for the
adequacy or accuracy of this release.
Contacts: Stem Cell Therapeutics Corp. Alan Moore, PhD President
and CEO (403) 245-5495 ext.224 Email: amoore@stemcellthera.com Stem
Cell Therapeutics Corp. Chloe Douglas-Crampton Investor Relations
(403) 245-5495 ext. 221 Email: crampton@stemcellthera.com Website:
www.stemcellthera.com
Sunvest Minerals Corp (TSXV:SSS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Sunvest Minerals Corp (TSXV:SSS)
Historical Stock Chart
From Jul 2023 to Jul 2024